draft me a clinical research protocol summary
- User
draft me a clinical research protocol summary
- Assistant
Here's a clinical research protocol summary following standard ICH-GCP format:
Clinical Research Protocol Summary
Protocol Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XR-123 in Adult Patients with Type 2 Diabetes Mellitus
Protocol Number
XR-123-301
Sponsor
PharmaCorp Therapeutics, Inc.
Phase
Phase III
Study Drug
XR-123 (Novel GLP-1 Receptor Agonist)
- Dosage Form: Oral tablet
- Strength: 15mg, 30mg
- Route: Oral administration
- Frequency: Once daily
Primary Objective
To evaluate the efficacy of XR-123 compared to placebo in reducing HbA1c levels in adult patients with inadequately controlled type 2 diabetes mellitus (T2DM).
Secondary Objectives
- To assess the effect of XR-123 on:
- Fasting plasma glucose
- Body weight
- Blood pressure
- To evaluate the safety and tolerability of XR-123
- To assess treatment satisfaction and quality of life
Study Design
- Multicenter, randomized, double-blind, placebo-controlled, parallel-group study
- 52-week treatment period
- 1:1:1 randomization (XR-123 15mg : XR-123 30mg : Placebo)
Study Population
Target Enrollment: 750 patients (250 per arm)
Key Inclusion Criteria:
- Adults aged 18-75 years
- Diagnosed with T2DM ≥6 months
- HbA1c 7.0-10.0%
- BMI 25-40 kg/m²
- On stable metformin therapy ≥3 months
Key Exclusion Criteria:
- Type 1 diabetes
- History of pancreatitis
- Cardiovascular event within past 6 months
- eGFR <60 mL/min/1.73m²
- Liver enzymes >2x ULN
Study Procedures
Screening Period (up to 28 days):
- Informed consent
- Medical history
- Physical examination
- Laboratory assessments
- ECG
- Vital signs
Treatment Period (52 weeks):
- 8 scheduled visits (Weeks 0, 4, 8, 12, 24, 36, 44, 52)
- HbA1c assessment at each visit
- Safety monitoring
- Patient-reported outcomes
- Drug dispensing and accountability
Follow-up Period:
- 30-day safety follow-up after last dose
Efficacy Assessments
Primary Endpoint:
- Change from baseline in HbA1c at Week 52
Secondary Endpoints:
- Change from baseline in:
- Fasting plasma glucose
- Body weight
- Systolic and diastolic blood pressure
- Proportion of patients achieving HbA1c <7.0%
- Treatment satisfaction questionnaire scores
Safety Assessments
- Adverse events and serious adverse events
- Physical examination
- Vital signs
- Clinical laboratory tests
- ECG
- Special interest AEs:
- Hypoglycemia
- Gastrointestinal events
- Pancreatitis
- Cardiovascular events
Statistical Considerations
Sample Size:
- 750 patients provides 90% power to detect a 0.5% difference in HbA1c between active treatment and placebo
- Assumes 15% dropout rate
Analysis Sets:
- Intent-to-treat (ITT)
- Per-protocol (PP)
- Safety population
Primary Analysis:
- MMRM (Mixed Model Repeated Measures)
- Multiple imputation for missing data
Ethical Considerations
- IRB/EC approval required
- Written informed consent mandatory
- Compliance with ICH-GCP guidelines
- Regular DSMB safety monitoring
Study Timeline
- First Patient First Visit: Q3 2024
- Last Patient Last Visit: Q4 2025
- Final Study Report: Q2 2026
Investigational Sites
- Approximately 75 sites
- Countries: United States, Canada, UK, Germany, France, Spain, Italy
Data Management
- Electronic Case Report Forms (eCRF)
- Central laboratory
- Interactive Response Technology (IRT) for randomization
- Regular data monitoring and cleaning
Quality Assurance
- Monitoring visits
- Source data verification
- Protocol deviation tracking
- Investigator training
Publication Policy
Results will be published regardless of outcome in accordance with:
- ICMJE guidelines
- ClinicalTrials.gov requirements
- Sponsor publication policy
Version: 1.0 Date: June 24, 2025 Status: Draft
Note: This is a template summary and should be modified according to specific study requirements and sponsor preferences.
Would you like me to elaborate on any particular section?